EN PL
REVIEW PAPER
Calprotectin in rheumatic diseases: a review
 
More details
Hide details
 
Submission date: 2016-11-25
 
 
Acceptance date: 2016-12-02
 
 
Online publication date: 2016-12-30
 
 
Publication date: 2016-12-30
 
 
Reumatologia 2016;54(6):306-309
 
KEYWORDS
TOPICS
ABSTRACT
Calprotectin also known as MRP8/14 or S100A8/A9 is a heterodimeric complex of two S100 calcium-binding proteins: myeloid-related protein 8 (MRP-8 or S100A8) and MRP-14 (or S100A9). At present, according to many authors, it is considered that calprotectin MRP8/14 is a potentially more sensitive biomarker of disease activity in rheumatoid disease than conventional inflammatory indices such as the erythrocyte sedimentation rate, C-reactive protein and others. A review of the literature on concentration of calprotectin in patients with some rheumatic diseases (rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still’s disease, systemic vasculitis, polymyalgia rheumatica, ankylosis spondylitis, systemic lupus erythematosus, and primary Sjögren’s syndrome) is presented.
 
REFERENCES (28)
1.
Vogl T, Tenbrock K, Ludwig S, et al. MRP8 and MRP14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
 
2.
Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980; 16: 273-282.
 
3.
Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113-123.
 
4.
Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and diseases activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994; 21: 733-738.
 
5.
Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1: 495-499.
 
6.
Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991; 20: 74-82.
 
7.
García-Arias M , Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis. Mol Diagn Ther 2013; 17: 49-56.
 
8.
Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis 2015; 74: 499-505.
 
9.
Guo Q, Zha X, Li C, et al. Serum calprotectin – a promising diagnostic marker for adult-onset Still’s disease. Clin Rheumatol 2016; 35: 73-79.
 
10.
Oktayoglu P, Bozkurt M, Mete N, et al. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med 2014; 62: 880-884.
 
11.
Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther 2016; 18: 160.
 
12.
Nordal HH, Brun JG, Halse AK, et al. Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren’s syndrome. Scand J Rheumatol 2014; 43: 76-78.
 
13.
Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 883-891.
 
14.
Haga HJ, Brun JG, Berntzen HB, et al. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 1993; 2: 47-50.
 
15.
Krzesiek E. Fecal calprotectin as an activity marker of inflammatory Bowel disease in children. Adv Clin Exp Med 2015; 24: 815-822.
 
16.
Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1093-1097.
 
17.
Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res 2016; 68: 899-906.
 
18.
Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology 2015; 54: 2239-2243.
 
19.
Joshua F, Edmonds J, Lassere M. Power Doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 2006; 36: 99-108.
 
20.
Iagnocco A, Finucci A, Ceccarelli F, et al. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. Rheumatology (Oxford) 2015; 54: 1890-1896.
 
21.
Szkudlarek M, Court-Payen M, Jacobsen S, et al. Inter observer agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 2003; 48: 955-962.
 
22.
Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford) 2013; 52: 1467-1476.
 
23.
Oktayoglu P, Mete N, Caglayan M, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest 2015; 75: 106-112.
 
24.
Hirono K, Foell D, Xing Y, et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease.
 
25.
J Am Coll Cardiol 2006; 48: 1257-1264.
 
26.
Brun JG, Madland TM, Gran JT, Myklebust G. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol 2005; 34: 125-128.
 
27.
Tantivitayakul P, Benjachat T, Somparn P, et al. Elevated expressions of myeloid-related proteins-8 and -14 are danger biomarkers for lupus nephritis. Lupus 2016; 25: 38-45.
 
28.
Tydén H, Lood C, Gullstrand B, et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford) 2013; 52: 2048-2055.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top